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Abstract 
We investigated the management and treatment of pregnant opioid users by Drug 
Treatment Services by region across England and Wales. A postal survey was conducted 
among 223 Community Drug Treatment Services (CDTS) across England and Wales. Sixty-
six percent CDTS responded (n=154/233) to the survey. Over half CDTS (55.3%) provided a 
maintenance methadone dose lower than that recommended for non-pregnant drug users. 
There were significant variations across regions and how professionals approached the 
management of pregnant opioid users. CDTS with an addiction specialist were significantly 
more likely (p<.01) to advocate high doses of methadone whereas those with a midwife, 
obstetrician or social worker involved were more likely (p<.05) to suggest low dose 
methadone and/or detoxification.  Service provision for pregnant opioid users is reliable and 
comprehensive but there is still variability in some aspects of the treatment received and the 
way in which methadone is prescribed is not always optimal.   
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Introduction 
In the UK there has been a steady increase of births to pregnant drug users from an 
estimated 568 births reported in 1995 (Morrison & Siney, 1995), rising to 1, 057 births in 
2003 (Advisory Council on the Misuse of Drugs, 2003) and 1, 970 in 2007 (Lakhani, 2009). 
Methadone for the treatment of opioid dependence in pregnancy has remained controversial 
since its early introduction in the 1960s with researches debating the benefits for the 
treatment of this complex group. However, methadone maintenance treatment has been the 
consensus adopted by the United States (Centre for Substance Abuse Treatment, 2009), 
Australia (New South Wales Department of Health, 2006), and the UK (Department of 
Health (England) and the devolved administrations, 2007) for the management of pregnant 
opioid dependent women. Nevertheless the benefits of methadone for the treatment of this 
group has remained controversial (McGlone, Mactier, & MacKinnon, 2008). Research 
pertaining to the effectiveness of methadone during pregnancy has been wide ranging but 
rarely systematic (Jones, O'Grady, Malfi, & Tuten, 2008). Ethical considerations coupled 
with cost have severely restricted the number of investigations that adequately covers the pre-
, peri- and post-natal periods (Wolff, Boys, Rostami-Hodjegan, Hay, & Raistrick, 2005). 
There have also been conflicting findings on fetal, neonatal and maternal outcomes of 
methadone maintained pregnant opioid users (DePetrillo & Rice, 1995; Drozdick, Berghella, 
Hill, & Kaltenbach, 2002; Hagopian et al., 1996; Kempley, 1995; Winklbaur et al., 2008). 
Arguments, supporting either high dose methadone during pregnancy (to avoid opioid 
withdrawal and fetal distress or relapse to illicit drug use), or challenging the benefits of this 
strategy by advocating low dose pharmacotherapy or detoxification (to reduce the occurrence 
of neonatal withdrawal), continue to be made (Nunn et al., 2009; Maas, Kattner, Weingart-
Jesse, Schafer, & Obladen, 1990).
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The UK Goverment Home Office, Professional and Non-Professional bodies, the 
Royal College of General Practitioners (Ford et al., 2005) and the Local Government Drugs 
Forum (ILGDF/SCODA), (Local Goverment Drugs Forum/Standing Conference on Drug 
Abuse. LGDF/SCODA, 1997) have suggested the need for integrated care. The 2007 UK 
Department for Health ‘Drug Misuse and Dependence: UK Guidelines on Clinical 
Management 2007’ (Department of Health (England) and the devolved administrations, 
2007) however contained little direct information for the management and treatment of 
pregnant drug users. And although the more recent National Institute for Health and Clinical 
Excellence (NICE) guidelines on pregnancy (National Institute for Health and Clinical 
Excellence (NICE), 2010) addressed many of the issues surrounding the provision of services 
for this complex group, its remit did not include pharmacotherapy for opioid dependence 
during pregnancy.  
There is international consensus on the effectiveness of fixed daily doses of between 
60-120mg methadone for dependent drug users (Faggiano, Vigna-Taglianti, Versino, & 
Lemma, 2003), however, there is no such accord for those who are pregnant. This creates an 
unnecessary ambiguity for the clinician who faces a dosing dilemma; the benefits of high 
dose methadone against its possible association with a neonatal abstinence syndrome (NAS). 
Little has been recorded in England and Wales about prescribing practices for opioid 
dependent addicts who become pregnant. In light of the absence of information about this 
vulnerable population we investigated the provision of services for pregnant opioid 
dependent women and in particular how Community Drug Treatment Services (CDTS) 
address the issue of pharmacotherapy.  
Method 
 A list of 387 different drug treatment services across England and Wales was 
identified from Drugscope’s helpfinder (www.drugscope.org.uk/resources/helpfinder  - 
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accessed October 2006). Those that did not provide prescribing services including services 
for young people, rehabilitation centres, special population services and prison services were 
excluded. As a result, 233 Community Drug Treatment Services (CDTS) were identified as 
the target population. A coded bespoke questionnaire was distributed via postal address to the 
managers of the CDTS in three different mailings between November 2006 and May 2007. 
The questionnaire sought information about service structure (capacity and professionals 
involved), current policies within the organisation, management and pharmacotherapy for 
pregnant opioid users. Ethical approval was obtained from the Joint South London & 
Maudsley NHS Foundation Trust and Institute of Psychiatry Research Ethics committee (Ref 
299/03 COREC 04/Q0705/22). 
Statistical analysis 
Descriptive and chi square modelling was used for the first stage of the analysis and 
chi square testing and one by one correlational techniques used for comparing binary 
variables. Difference between CDTS was also assessed for statistical significance using 
Mann-Whitney U-test or Kruskal-Wallis as appropriate. Logistic regression models were 
used to determine factors that influenced service provision (service demographics, staff 
profession, number of clients and prescribing policy etc). In contingency tablets larger than 
2X2, a chi-square test was used if fewer than 20% of the expected frequencies were less than 
five and no expected frequency was less than one. Where this requirement was not met the 
recommendation of Siegel and Castellan (Siegel & Castellan, 1988) and others (Bland, 1987; 
Kirkwood, 1988) was followed and, wherever appropriate, categories were combined to 
reduce the number of cells to a 2x2 table thus increasing the expected frequencies. This 
recommendation was used particularly to compare regions when contingency tables were 10 
x 2 and the chi-square test revealed a significant difference but assumptions were not met.  
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Results 
 Sixty-six percent of CDTS managers (n = 154/233) responded to the survey 
representing 8 key regions in England & Wales (see Table 1). Seventy three percent of CDTS 
reported treating ≤ 10 pregnant drug users at any one time (40% treating ≤ 5). At the time of 
the survey the remaining 27% CDTS reported having >10 pregnant opioid addicts in their 
service. 
Service provision  
A considerable proportion of pregnant drug users were already known to CDTS 
and/or presented during the first trimester of pregnancy (72.5%). Only a small minority 
(7.4%) reported referrals as a consequence of a late presentation of pregnancy. Most women 
(81.2%) self-referred although managers also reported referrals from GPs (73.4%), antenatal 
clinics (68.8%), social services (57.8%) and the criminal justice/probation service. 
Service Structure 
 The composition of CDTS varied but predominantly comprised a prescribing doctor 
(96%), and drug and alcohol nurses (89.5%); many CDTS reported having a pregnancy 
addiction specialist (60%), who was often a drug and alcohol nurse (77.2%). Sixty-four 
CDTS (42%) reported having a specialist clinic for pregnant drug users In addition, almost 
half CDTS had a drug counsellor (48.4%) and/or a drug worker (43%). Clinical Psychologists 
(CP) and Community Psychiatric Nurses (CPN) were also reported as part of the team 
(32.0% and 31.4%, respectively). Service managers reported having close links with 
community midwives (83.0%), obstetricians (65.4%) and social services (65.4%).  
Methadone 
Methadone pharmacotherapy was the treatment of choice (97.4%, 148/152) for 
pregnant women whilst buprenorphine (67.8%) was also commonly prescribed but only 35% 
of CDTS offered ‘maintenance’ dosing to pregnant women, and 10.6% stabilization followed 
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by detoxification (see Figure 1). Induction onto methadone varied: 53.6% managers reported 
initial dosing of between 30-40 mg methadone/day and others (21.9%) <30mg 
methadone/day Most CDTS (70.2%) advocated methadone maintenance treatment (MMT) 
for opioid dependent pregnant women. Two strategies for MMT were apparent; maintenance 
of a fixed daily dose ≤ 50 mg methadone/day (55.3%, CDTS) or prescription of the lowest 
possible fixed daily dose (52.8%, CDTS).  CDTS with pregnancy addiction specialists and/or 
drug counsellors were twice (OR 2.61 v OR 2.19) as likely to recommend MMT regardless of 
the presenting dose ([X² (1, n=150) = 7.09, P <.008, Phi=.217] and [X² (1, n=151) = 4.64, P 
<031, Phi=.175], respectively). Compared to other CDTS those who reported a higher 
proportion of midwife involvement were 2.38 times more likely [X² (1,n=150)= 3.98, P <046, 
Phi=.163] to advocate low daily dosing with methadone.  
One third of managers (33.6%) reported that their service had a ‘high- dose’ policy 
for pregnant women: reporting a total mean maximal dose of 138mg (SD + 35.7mg) 
methadone/day. CDTS that shared care with non-specialist midwives reported prescribing a 
significantly (P <014) lower maximum daily dose of methadone (median 120 mg/day). Most 
CDTS (93.2%) reported that they would increase the daily dose of methadone if a pregnant 
woman complained of opioid withdrawal symptoms during the third trimester, with 91.4% 
prescribing increments of between 5-10 mg methadone/day. Managers reported that CDTS 
also recommended splitting the daily methadone dose (61.9%); and some advocated 
alternative therapies (13.6%, 20/147). A small number advised ‘coping’ with opioid 
withdrawal symptoms rather than offer an intervention (6.1%, 9/147). 
  Many CDTS (65.5%) also employed gradual methadone dosage reduction during 
pregnancy. A policy of methadone stabilisation followed by detoxification was reported by 
34.4% of CDTS managers. The odds of receiving this dosage regime was significantly 
greater (OR 3.16 v OR 3.19) if midwives [X² (1, n=150)= 4.33, P<037, Phi=.170,] or if 
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neonatologists  [X² (1, n=150)= 9.72, P <002, Phi=.255,] were involved in treatment 
planning. Prescribing decisions were also influenced by concern about the neonatal 
abstinence syndrome (NAS). Of those services (41%) that believed the onset and severity of 
NAS were associated with methadone dose, the majority (96.5%) had a policy of prescribing 
<30 mg day. Services that had an in-house policy for pregnant women were significantly 
more likely [X2 (1, N=134) = 3.91, P < 048, Phi = -174] to report that there was no 
association between methadone dose and NAS and prescribed higher doses  
  Community-based opioid detoxification was offered by 23.8% of CDTS overall and 
inpatient opioid detoxification by 37% CDTS. Inpatient detoxification was significantly 
associated with the involvement in the service of neonatologists [X² (1, n=150) = 6.43, P 
<.011, Phi=.207, OR= 2.55], specialist liaison midwives [X² (1, n=150)= 5.34, P <021, 
Phi=.188, OR= 2.22] or social workers [X² (1, n=150)= 4.48, P <034, Phi=.172, OR= 2.18]. 
The model containing both neonatologists and social workers was significant [.X² (2,N=150) 
= 9.72, P <008) and explained between 6.3% (Cos and Snell square) and 8.6% (Nagelkerke R 
squared) of the variance in flexibility with methadone dosing and correctly classified 67.3% 
of managers responses. However, only the variable ‘neonatologist’ made a unique 
statistically significant contribution to treatment and when a neonatologist was involved 
CDTS were 2.28 times more likely to offer inpatient detoxification.  
Buprenorphine 
Although buprenorphine was commonly prescribed (67.8%) for pregnant opioid dependent 
women, only 35% of CDTS offered ‘maintenance’ dosing, and even fewer (10.6%) 
stabilization followed by detoxification. 
Benzodiazepines 
Many CDTS (60%) reported prescribing benzodiazepines to pregnant drug users. 
There was a significant association (P <027) between having an in-house clinic specifically 
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for pregnant women and prescribing benzodiazepines. CDTS with a pregnancy addiction 
specialist were twice (OR= 2.18) as likely to prescribe benzodiazepines as those without an 
appointed in-house specialist service [X ² (1, n=149) = 6.84 P <027, Cramer’s V= .18].  
Discussion 
This is the first study to investigate the treatment provision, by CDTS, offered to 
pregnant opioid users in England and Wales. Service managers reported that CDTS were 
multidisciplinary in nature and heterogeneous in composition. Integrated care services such 
as those reported here are advocated as an effective model of care in the UK (National 
Institute for Health and Clinical Excellence (NICE), 2010; Becker & Duffy, 2002), and 
indeed practice in many areas was very good with the majority of pregnant opioid users 
accessing CDTS and antenatal services during their first trimester. Overall CDTS appeared to 
have the necessary competences to provide a service for this complex population. MMT was 
the treatment of choice for the majority of CDTS in line with the UK National guidelines, 
which at the time recommended “low dose maintenance for pregnant opioid users” (pp 82, 
1999) (Department of Health (England) and the devolved administrations, 1999) later 
amended to “maintenance at a dose that stops or minimises illicit use" (pp 81 7.4.7.1; 2007) 
(Department of Health (England) and the devolved administrations, 2007). However, dosing 
decisions by some CDTS were significantly different from the national guidelines and at odds 
with the scientific evidence, with implications for maternal and fetal outcome. Dosing 
strategy was largely dependent upon the professional profile of the treatment service. For 
instance, the role of both the neonatologist and the social worker was significant [.X² (2, 
N=150) = 9.72, P <008) and classified 67.3% of managers responses.  
Although treatment practices have been investigated internationally [18, 28-29], little 
has been reported about community-based services for pregnant women in the United 
Kingdom. The Advisory Council on the Misuse of Drugs (ACMD) (Advisory Council on the 
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Misuse of Drugs, 2003) described the provision of services for this complex group in 2003 
however, only 20% of respondents to that survey were prescribing services. This CDTS 
survey was conducted on a nationally representative sample where sampling error was 
minimised by selecting only community-based services that provided substitute 
pharmacotherapy. In addition, a response rate of 66% was achieved overall which is above 
the response rate considered acceptable for self-completion questionnaires (Sitzia & Wood, 
1998). Selection bias may have been present amongst those service managers who chose to 
take part but this was thought unlikely since this study substantiates work conducted on 
individual clinics in the field. The survey was however conducted just prior to the publication 
of the 2007 National guidelines (Department of Health (England) and the devolved 
administrations, 2007), although these were not significantly different from those published 
in 1999 (Department of Health (England) and the devolved administrations, 1999). 
Even though methadone detoxification during pregnancy has remained controversial, 
this approach was frequently reported by CDTS managers. Both inpatient (offered by 37% 
CDTS) and outpatient (24% CDTS) detoxification and detoxification following stabilisation 
(34% CDTS) were reported. Opioid detoxification has been contra-indicated in both the first 
trimester of pregnancy because of the risk of miscarriage and in the last trimester because of 
the possibility of precipitating pre-term labour, fetal distress, and even stillbirth (Department 
of Health (England) and the devolved administrations, 2007). However, Young (Young, 
2007) revealed that the underlying evidence was tentative at best and based on two case 
studies that had low scientific power (n = 1) and no controls (Rementeria & Nunag, 1973; 
Zuspan, Gumpel, Mejia-Zelaya, Madden, & Davis, 1975). The Royal College of General 
Practitioners’, using evidence from a comparison of two self-selected Scottish groups 
(Hepburn, 1997), suggest that methadone detoxification can be carried out ‘at any speed and 
at any stage’ during pregnancy (Ford et al., 2005). Others highlight nevertheless the poor 
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maternal treatment outcomes observed following opioid detoxification, such as the high rate 
of relapse back to illicit drug use (Kashiwagi, Arlettaz, Lauper, Zimmermann, & Hebisch, 
2005), which has been widely observed to be detrimental to neonatal outcomes (Hulse, 
Milne, English, & Holman, 1997; Unger et al., 2011). In this survey the likelihood of a CDTS 
recommending inpatient detoxification was doubled (0R = 2.28) when neonatologists, were 
involved in patient care. The rationale for this treatment approach was not reported but it may 
have been that neonatologists like other clinicians, sought to err on the side of caution and 
advocate detoxification to avert the fear of fetal sedation or NAS. Variability in the way that 
national drug policy is interpreted was evident from our respondents, a finding that 
substantiates qualitative research in the UK (Klee, 2002), which reports that conflicting 
advice is given to pregnant opioid users by different healthcare professionals. Further work is 
required to establish the effectiveness of methadone detoxification for this population. 
High-dose MMT during pregnancy, on the other hand, has been associated with 
positive outcomes such as ‘normal’ gestational birth weight and head circumference 
(Hagopian et al., 1996; Hulse et al., 1997; Wittmann & Segal, 1991), reduced neonatal 
complications and a shorter period of hospitalisation (Igboekwu & Wolff, 2010). Indeed 
leading researchers in North America advocate a policy of high-dose therapy for pregnant 
opioid users (Drozdick et al., 2002). In the UK, the 2007 NICE guidelines: ‘Methadone and 
buprenorphine for the management of opioid dependence’ (National Institute for Health and 
Clinical Excellence (NICE), 2007), recommended fixed daily dosing of 60 to 110 mg 
methadone as optimal therapy for opioid dependent addicts. Evidence from North America 
suggests that these dosage regimes could be safely applied to pregnant women in the UK, 
who demonstrate appropriate severity of dependence, yet only a third of our CDTS had a 
high-dose MMT policy. Decisions concerning high doses were significantly more likely 
when healthcare professionals with specialist knowledge such as pregnancy addiction 
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specialists and addiction counsellors (OR 2.61 and OR 2.19, P <008, respectively) were 
involved, suggesting that expertise and training is important for the care of these women. 
There was greater consistency of care concerning withdrawal symptom complaints during the 
last trimester of pregnancy with 93% CDTS advising pharmacological intervention and/or 
division of the daily dose However, practice elsewhere has not followed this policy and in 
Scotland, with multiple agency support, women reportedly managed dosage reductions in the 
later stages of pregnancy, without clinical intervention (Hepburn, 2002).  
More systematic work is required to familiarise healthcare professionals, policy 
makers and commissioners with the evidence that demonstrates the benefit of high-dose of 
MMT during pregnancy. Keeping drug addicts in treatment is accepted by the UK National 
Audit Office as being cost-effective; saving £1 for every £2.50 spent on treatment (National 
Audit Office, 2010; Barnard, Webster, O'Connor, Jones, & Donmall, 2009). Furthermore, in 
the interests of maternal and infant welfare definitive evidence must be gathered that 
abstinence is sustainable in the post natal period following detoxification treatment. Although 
prescribing decisions are, by their nature individually formed, advocates of detoxification 
may overestimate the ability of the newly abstinent mother to cope with child rearing as well 
and the process of recovery from a chronic relapsing condition. Research in the British 
context of the community-based drug treatment service should be urgently commissioned to 
clarify dosing strategies for pregnant addicts, replicating North American work if necessary. 
Further consideration also needs to be given to the influence of different disciplines in 
prescribing decisions and more stringent efforts should be made to ensure that all healthcare 
professionals involved in the care of pregnant opioid dependent women are aware and work 
within the national clinical guidelines for substance misuse and dependence. There remain 
many conflicting messages remain for those charged with the care of pregnant opioid users 
and a need for consensus on how to manage this population is urgently required. 
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Response rates from community drug treatment services (CDTS) by regions in England 
& Wales 
 
London 65.6% (21/38)  East Midlands  58.3% (7/12) 
South West  81.8% (9/11)  Yorkshire & Humber 77.0% (20/26) 
South East 65.6% (21/32)  North East 94.7% (18/19) 
East Anglia 65.0% (13/20)  North West 52.3% (22/42) 
West Midlands  66.7% (14/21)  Wales 75.0% (9/12) 
England & Wales 66.1% (154/233) 
 
Note: The response rates represent the proportion of respondents from the total of community 



























Treatment options offered to pregnant opioid dependent users by community drug 
treatment services (CDTS) in England and Wales 
 
 
Figure 1. Percentage of community drug treatment services (CDTS, N=154) offering 
different treatment options to pregnant opioid users. ID= Inpatient Detoxification; CD= 
Community Detoxification; BM= Buprenorphine Maintenance; BSD= Buprenorphine 
Stabilisation following by Detoxification; MM= Methadone Maintenance; MML=Methadone 

























ID CD BM BSD MM MML MSD
Running Head: SERVICE PROVISION FOR PREGNANT ADDICTS                                1 
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